Download PDF
Thromb Haemost 1987; 57(03): 326-328
DOI: 10.1055/s-0038-1651126
Original Article
Schattauer GmbH Stuttgart

Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects

Ph Vague
1   The Service de Médecine Interne et Nutrition, Hôpital Michel Levy, France
,
I Juhan-Vague
2   The Laboratoire d’Hématologie, CHU Timone, University of Marseille Medical School, France
,
M C Alessi
2   The Laboratoire d’Hématologie, CHU Timone, University of Marseille Medical School, France
,
C Badier
1   The Service de Médecine Interne et Nutrition, Hôpital Michel Levy, France
,
J Valadier
2   The Laboratoire d’Hématologie, CHU Timone, University of Marseille Medical School, France
› Author Affiliations
Further Information

Publication History

Received 22 December 1986

Accepted after revision 24 February 1987

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have previously observed a positive correlation between Plasminogen Activator Inhibition capacity (PA Inhibition), Body Mass Index (BMI) and plasma insulin levels in a population of non diabetic subjects. The anti diabetic biguanide Metformin which decreases insulin resistance has been reported to increase the blood fibrinolytic activity. Therefore we have studied the effect of Metformin on PA Inhibition levels in obese subjects with normal glucose tolerance. Eighteen obese women (O) (BMI: 31.4 ± 1.13, m ± S.E.M.) were compared to age matched controls (C) (BMI: 20.2 ± 0.8) and randomized to a 15 days treatment by Metformin (M) (1.7 g/day) or placebo (P) in a double blind study while on a weight maintaining diet. O compared to C had higher levels (m ± S.E.M.) of PA Inhibition (9 ± 1.8 IU/ml, versus 2.88 ± 0.29 p <0.01), lower euglobulin fibrinolytic activity (EFA) (4.95 ±1.17 mm versus 9 ± 0.29 p <0.05), higher plasma insulin (24.1 ±2.1. uU/ml), versus 12 ± 1 p <0.01) and triglyceride (1.32 ± 0.16 mmol/1, versus 0.8 ± 0.08 p <0.05). After 15 days of treatment, in group M a significant decrease in PA Inhibition (5.51 ± 1.4, versus 9.48 ±2.1 p <0.05) in plasma insulin (18.5 ±0.1, versus 24.5 ± 3.5, p <0.05) and plasma triglyceride (1.08 ± 0.1, versus 1.47 ± 0.3 p <0.05) and an increase in EFA (6.50 ± 0.28, versus 5.25 ± 0.35 p <0.05) were observed. No significant variation was observed in group P.

Keywords

Fibrinolysis - Obesity - Metformin - Plasminogen activator inhibition
 

  • References

  • 1 Shaw DA, Naughton D. Relationship between blood fibrinolytic activity and body fatness. Lancet 1963; 1: 352-354
    PubMedGoogle Scholar
  • 2 Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary artery disease. Lancet 1965; 2: 256-259
    PubMedGoogle Scholar
  • 3 Vague Ph, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi C, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 2: 250-253
    PubMedGoogle Scholar
  • 4 Bagdade J, Bierman EL, Porte D. The significance of basal insulin levels in the evolution of insulin response to glucose in diabetic and non diabetic subjects. J Clin Invest 1967; 46: 1549-1544
    CrossrefPubMedGoogle Scholar
  • 5 Vague Ph. Effect d’une dose unique de Metformin sur la tolérance au glucose des sujets normaux ou obèses. Le Diabete 1970; 18: 35-39
    PubMedGoogle Scholar
  • 6 National diabetes data group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1038-1057
    PubMedGoogle Scholar
  • 7 Kluft C, Brakman P, Veldbuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fraction on the fibrin plate. In Progress in chemical fibrinolysis and thrombolysis. Davidson JF, Samama MM, Desnoyer PC. (eds.), pp 57-65 Raven Press; New York: 1967
    Google Scholar
  • 8 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedGoogle Scholar
  • 9 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for Tissue Plasminogen Activator (t-PA). Thromb Haemostsas 1985; 53: 134-136
    PubMedGoogle Scholar
  • 10 Bucolo G, David M. Quantitative determination of serum triglyceride by use of enzymes. Clin Chem 1973; 19: 475-482
    PubMedGoogle Scholar
  • 11 Fearnley GR, Chakrabarti R, Avis P RD. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischemic heart disease and obesity. Br Med J 1963; 1: 921-923
    CrossrefPubMedGoogle Scholar
  • 12 Ogston DM, Andrew GM. Fibrinolysis in obesity. Lancet 1964; 2: 1205-1207
    PubMedGoogle Scholar
  • 13 Grace CS, Goldrick RB. Fibrinolysis and body build. Interelationships between blood fibrinolysis. Body composition and parameters of lipid and carbohydrate metabolism. J Atheroscl Res 1968; 8: 705-719
    CrossrefPubMedGoogle Scholar
  • 14 Warlow CP, McNeill A, Ogston D, Douglas AS. Platelet adhesiveness, coagulation and fibrinolytic activity in obesity. J Clin Pathol 1972; 25: 484-486
    CrossrefPubMedGoogle Scholar
  • 15 Almer LO, Janzon L. Low fibrinolytic activity in obesity. Thromb Res 1975; 6: 171-175
    CrossrefPubMedGoogle Scholar
  • 16 Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann NY Acad Sci 1965; 131: 357-373
    CrossrefPubMedGoogle Scholar
  • 17 Coccheri S, Cacciari E, Fortunato G, Bergamaschi R, Balsamo A, Lipollani F, Poggi M. Fibrinolytic response to venous occlusion and other haemostatic studies in obese children. Progress in fibrinolysis. Davidson JF, Nilsson IM, Astedt B. (eds.). pp 347-350 Churchill Livingstone; Edinburgh - London - Melbourne - New York: 1981
    Google Scholar
  • 18 Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G. Effect of Metformin treatment of erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects in type I and type II diabetic patients. Diabète et Métabol 1986; 12: 219-224
    PubMedGoogle Scholar
  • 19 Lord JM, White SI, Bailay CJ, Atkins TW, Fletcher RF, Taylor KG. Effect of Metformin on insulin receptor binding and glycaemic control in type II diabetes. British Medical Journal 1983; 286: 830-831
    CrossrefPubMedGoogle Scholar
  • 20 Gustafson A, Bjorntorp P, Fahlen M. Metformin administration in hyperlipidaemic states. Acta Med Scand 1971; 190: 421-424
    PubMedGoogle Scholar
  • 21 Sirtori ER, Tremoli E, Sirtori M, Conti F, Paoletti R. Treatment of hypertriglyceridaemia with Metformin. Atheroscler 1977; 26: 583-592
    PubMedGoogle Scholar
  • 22 Goldberg RB. Lipid disorders in diabetes. Diabetes Care 1981; 4: 561-572
    CrossrefPubMedGoogle Scholar
  • 23 Hocking ED, Chakrabarti JE, Fearnley GR. Effect of biguanides and atromid on fibrinolysis. J Atheroscl Res 1967; 7: 121-130
    CrossrefPubMedGoogle Scholar
  • 24 Hamsten A, Wiman B, De Faire U, Blombàck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Eng J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 25 Ahmad M, Saku K, Glas-Greenwalt P, Kashyap ML. Inhibitor and activator of plasminogen in patients with hyperlipoproteinemias. Thromb Haemostas 1985; 54: 266 (Abstr n° 158)
    PubMedGoogle Scholar
  • 26 Haglund O, Wibell L, Saldeen T. Plasminogen activators and inhibitors of the plasminogen activators in patients with deep venous thrombosis. Diurnal variation of the inhibitor. Thromb Haemostas 1985; 54: 270 (Abstr n° 1604)
    PubMedGoogle Scholar
  • 27 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA Inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
    PubMedGoogle Scholar
  • 28 Ducimetiere P, Eschwege E, Richard J, Rosselin G, Claude JR. Clinical complications of coronary heart disease according to plasma insulin and glucose levels. A further analysis of the Paris prospective study. In Advance in Diabetes Epidemiology. Eschwege E. (eds.) Elsevier Biochemical Press; Amsterdam: 1982: 149-155
    Google Scholar
  • 29 Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol 1946; 58: 207-212
    CrossrefPubMedGoogle Scholar
  • 30 Chakrabarti R, Fearnley GR, Hocking ED, Deliheo SA, Clarke G. Fibrinolytic activity related to age in survivors of myocardial infarction. Lancet 1966; 1: 573-574
    PubMedGoogle Scholar
  • 31 Rosing DR, Redwood DR, Brakman P, Astrup B. Impairment of the diurnal fibrinolytic response in man. Effects of aging, type IV hyperlipoproteinaemia, and coronary artery disease. Circ Res 1973; 32: 752-758
    CrossrefPubMedGoogle Scholar
  • 32 Peabody RA, Tsapogas MJ, Wu KT. Altered endogenous fibrinolysis and biochemical factors in atherosclerosis. Arch Surg 1974; 109: 309-313
    CrossrefPubMedGoogle Scholar
  • 33 Pilgeram LO. Abnormalities in clotting and thrombolysis as a risk factor for stroke. Thromb Haemostas 1974; 31: 245-264
    PubMedGoogle Scholar
  • 34 Bouisson H, Thiers JC, Douste-Blazy L, Pieraggi MT, Julian M. Chronic lathyrism and atheromatosis in the rat. Protective effect of Metformin Gerontology 1980; 26: 188-199
    PubMedGoogle Scholar